ABSTRACT IL-16 is a ligand and chemotactic factor for CD4 + T cells. IL-16 inhibits the CD3 mediated lymphocyte activation and proliferation. The effects of IL-16 on the target cells are dependent on the cell type, the presence of co-activators etc. To understand the regulation function and mechanism of IL-16 on target cells, we used a 130 a.a. recombinant IL-16 to study its effects on the growth of Jurkat T leukemia cells in vitro. We found that the rIL-16 stimulated the proliferation of Jurkat cells at low dose (10 
INTRODUCTION
Pro-IL-16 is a 631 amino acid precursor molecule [1] , [2] , which can be cleaved by caspase into two parts. The N-terminal part is kept in the cytoplasm [3] , and the C-terminal is a secreted peptide containing 121 amino acids. Researches have shown that the recombinant IL-16 C-terminal 130 a.a. has same bioactivity as the natural secreted human IL-16 [1] , [4] , [5] .
The human secreting IL-16 is the natural soluble ligand of CD4 molecule [4] , [6] , [7] . It stimulates a series of signals mediated by CD4, resulting in the activation of p56lck, increases of intracellular Ca ++ and phosphatidylinositol 1, 4, 5-trisphosphate and the increased expression of IL-2 receptor [4] , [8] [9] [10] . The signals by CD4 can activate the T cell when there is another co-stimulator. The cross-linking of cell surface CD4 with anti-CD4 mAb or HIV-1 gp120 may mediate apoptosis rather than activation of the CD4 + T cell [11] [12] [13] [14] [15] . Interestingly, another cytokine, IL-2, can also prime T cells for cell death in addition to its activity in activation and proliferation of T cells [16] . All those results indicated that the activation and cell death are conditional events, the difference is very much dependent on the amount of stimuli, cell type, and the presence of co-activators etc.
As reported here, we have investigated the possible role of rIL-16 to Jurkat T leukemia cells. We found that the rIL-16 showed the growth-stimulating activity at 10 
MATERIALS AND METHODS

Cells and cultures
Jurkat T leukemia cells were from Shanghai Cell Bank, Chinese Academy of Sciences. The cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 25 mM HEPES buffer, 100 U/ml penicillin, and 100 μg/ml streptomycin.
Antibodies
Anti-IL-16 monoclonal antibody was a product from Yes Biotech Lab, Canada. Rabbit anti human CD4, CD8, FasL antibodies, and FITC-conjugated goat anti-rabbit Ig were purchased from Santa Cruz Biotech. Inc.
Recombinant human IL-16
Human PBMCs were obtained from the venous blood of healthy normal human volunteers by density centrifugation on Ficoll-Paque (Pharmacia Fine Chemicals).
RNA was isolated from PHA-stimulated PBMC cells using Trizol (Gibco/BRL). Reverse transcription was performed in 30 l final volume containing 0.5 g total RNA which was incubated for 15 min at 65 before addition of 0.25 m M mix dNTPs, 1× reverse transcriptase (RT) buffer (MBI Fermentas), RNasin (4U), DTT 10 mM, random primer 2 μM and 10U M-MLV RT( MBI Fermentas). The reaction was allowed 1 h at 37 and 5 min at 95 . The cDNA product of reverse transcription was amplified in the presence of IL-16-specific primers flanked with a BamH 1 site at 5' end of forward and a Cla 1 site at 3' end of reverse. The primers were 5'-CGC GGA TCC ATG CCC GAC CTC AAC TCC-3' and 5'-CCA TCG ATC AGC ATG TCC TGC CTA GGA G-3'. Then, the PCR product was digested with BamH 1 and Cla 1, and cloned into pBluescript (SK) vector. After sequence confirmation, the IL-16 fragment was re-cloned into E.coli expression vector pT7-7His and expressed in BL-21 cells under IPTG induction.
RT-PCR analysis of gene expression
We adopted semi-quantitative RT-PCR to detect the expression level of the target genes. β-actin was used as internal control. cDNA (1 μl) was added to reaction mixtures (50 μl total volume) containing 1×PCR buffer, 200 μM dNTPs (Pharmacia Biotech), 1 μM of forward and reverse primers, 5U Taq DNA polymerase, and 1.5 mM MgCl 2 . The primers are as follows: 
Western blot analysis
The protein extractions were analyzed by Western blot. In brief, 10 mg of total protein extract of Jurkat cells was separated by SDS-PAGE, transferred onto nitrocellulose membrane and probed with mouse anti-FasL monoclonal antibody and second antibody. Finally, the band was developed with diaminobenzidine.
PI stain and FACS
Jurkat cells (5×10 6 /ml) were washed twice with PBS and incubated for 25 min at 4 with 4% formaldehyde. After three washes in PBS, cells were incubated with fresh PI stain solution (5 μg/ml PI and 50 μg/ml RNaseA in PBS pH 7.4) for 15-20 min in dark at room temperature. Then, cells were examined in fluoroscope or used for flow cytometry analysis, with FACS calibur and analysis software CELLQuest (Becton Dickinson).
Cell counting and MTT assay
The effects of IL-16 to Jurkat cells were detected by cell counting and MTT assay. In cell counting experiment, 3 μl of 1×10
6 Jurkat cells/ml were cultured in different concentrations of rIL-16-containing RPMI-1640 without serum for three days. Cell numbers were counted in a haemocytometer in the presence of 0.5% trypan blue. The experiment was repeated at least 6 times. The specific inhibitors, 0.15 μM Bisindolylmaleimide (Bis) for PKC, 0.25 μM PD98059 (PD) for MEK, 8 mM SB203580 (SB) for p38, were added into medium 1.5 h before rIL-16 to examine the possible regulators and associated signal pathway responsible to the rIL-16 action in the cells. After 24 h treatment, cells were harvested for MTT assay. Briefly, MTT was dissolved at a concentration of 5 mg/ml in sterile PBS. Extraction buffer was composed of 20% W/V of SDS (AMRESCO) in 50% of DMF (Fluka). pH was adjusted to 4.7 by adding 2.5% of 80% acetic acid and 2. 5% of 1N HCl. Each well was added 25 μl MTT stock solution, incubated at 37 for 4 h, then added 100 μl of the extraction buffer. After an overnight incubation at 37 , the optical densities at 570 nM were measured using ELISA Microplate Reader (BIO-RAD Model 450).
RESULTS
rhIL-16
The recombinant human IL-16 have been expressed and purified was a 130 a.a. fragment beginning from Met at site 502 and ended until 631 of pro-IL16, which has been shown to be sufficient for the biologic activity of IL-16 [17] , [18] .
IL-16 expressing vector transformed BL21 (DE3) cells were cultured in Terric Broth medium. When the OD600 reached 0.6-0.7, 1 mM IPTG was added to induce the expression of IL-16 for another 4 h before harvest. Coomassie blue staining of SDS-PAGE of the harvested cell extract detected a protein with the proper 18 kD molecular weight ( Fig  1A) . Western blot confirmed the 18 kD protein specifically interact with anti-IL-16 monoclonal antibody ( Fig 1B) indicating that the recombinant protein showed the predicted molecular weight and immunological activities of human IL-16.
The recombinant IL-16 was further purified by affinity chromatography on Ni 2+ -NTA agarose (Qiagen), and was evaluated to be more than 95% purity by silver staining (data not shown). Fractions were tested for activation of PBMCs proliferation according to Parado s method [19] , and the results confirmed that the recombinant IL-16 has the human IL-16 biologic activity (data not shown).
The effects of rhIL-16 on the growth of Jurkat T leukemia cells
To confirm the potential response activity of Jurkat cells to IL-16 treatment, the surface marker molecules of the cells was detected by flow cytometry with anti-CD4 and anti-CD8 monoclonal antibodies. As shown in Fig 2, the Jurkat cells used in the ex- M rIL-16 compared with control showing the stimulating activity of rIL-16 to M) had the inhibiting effect to the cells (Fig 4) .
Higher concentration rIL-16 treatment resulted in an enhanced apoptosis To Jurkat T leukemia cells, rIL-16 showed either growth-stimulating activity at low dose (10 -9 M) or growth-inhibiting activity at high dose (10 The FACS assay indicated a low ratio of spontaneous apoptosis of Jurkat cells in serum-free medium (Fig 5A) . Low concentration (10 
M)
of rIL-16 treatment showed no significant change of cell apoptosis in 24 h (Fig 5B, C) . But, under 10 
Signal transduction pathway involved in rIL-16 action on Jurkat cells
To understand the signal pathways involved in the growth-stimulating or growth-inhibiting activities of rIL-16 on Jurkat cells, the possible role of PKC and ERK were investigated. 
PKC is a Ca
2+ dependent Ser/Thr kinase. It is activated in cell proliferation, differentiation, and migration [10] . We used the PKC specific inhibitor 
DISCUSSION
Human IL-16 functions as a pleiotropic regulator stimulating the proliferation, activation, chemotaxis and programmed cell death on T lymphocytes. The signals to T cell are all mediated by its natural receptor CD4. The role of CD4 in the regulation of cell activation and death is pretty complex.
We report here the recombinant IL-16 may stimulate the proliferation of Jurkat T leukemia cells at 10 -9 M and potentially inhibit the cell growth accompanied by an increased apoptosis under 10 -5 M of IL-16 induction. The inhibiting effects of IL-16 on CD3-dependent lymphocyte activation and proliferation were previously reported [8] , [22] . Cross-linking of the CD4 molecule by anti-CD4 mAb or by HIV envelope protein gp120 has been shown to prime resting CD4
+ T lymphocytes for apoptosis [24] , [25] . While the opposite effects on activated T cell was also observed, ligation of CD4 by anti-CD4 mAb or HIV-1 gp120 drastically inhibited subsequent AICD (Activation Induced Cell Death) of human T cell clones triggered through CD3/TCR, due to the prevention of up regulation of FasL [25] , [26] . Similarly, CD3/CD4 co-ligation was shown to inhibit T-cell activation in the absence of a costimulus in mouse lymphocytes [27] . In a word, the presence of costimulus and the subsequent events of stimulus may direct the cell to activation or death. Based on these former results, it could be postulated that IL-16 may also function as a stimulus for apoptosis besides its activation effect on CD4 + T cells. Various members of the interleukin family, like IL-2, have been shown to possess both anti-apoptotic and pro-apoptotic stimulation activity [16] . IL-2 can induce proliferation in most circumstances, but it has also been reported that IL-2 can down-regulate the caspase-8 inhibitor c-FLIP [23] , and up-regulate FasL [16] , both molecules can prime cells for death.
Several studies have shown the expression and interaction of Fas and FasL can result in the autocrine stimulation of Fas/FasL death pathway in AICD in T hybridoma cells and activated T cells. Because Jurkat cells constitutively express Fas at their surface and are sensitive to Fas-induced apoptosis [21] , our research focuses on FasL expression. Surprisingly, rIL-16 doesn t up-regulate FasL, which correlate with AICD in Jurkat cells caused by most stimulators [21] , [29] [30] [31] [32] , but does down regulate its expression on both RNA and protein level. Although several studies have shown that the expression and interaction of Fas and FasL is required for AICD of activated T cells. But, Fas/FasL pathway is not an absolute requirement for death control [33] . These results also hint that there may be another apoptosis pathway functioning in the IL-16 mediated effects.
We found that c-myc and Bid expression level were up regulated by IL-16. This result suggested that cMyc might be involved in the process to activate certain cell death associated genes, but not FasL in this case. The Bcl-2 family proteins consist of both antagonists and agonists that regulate the apoptosis by competing through dimerization. Over-expression of Bcl-2 suppresses Fas-mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells and Trailinduced apoptosis in Jurkat cells [34] , [35] . Bid, one of the BH3 domain-containing molecules, promotes cell death after binding with Bcl-2 [34] , [36] . The upregulation of Bid in IL-16 treated Jurkat cells implied the involvement of Bid molecule in the cell death through other death receptors, tumor necrosis factor or Trail etc.
To figure out the special pathways associated with the regulation activity of IL-16 in Jurkat cells, we found that PKC was activated after IL-16 treatment, and ERK pathway is also required for control of rIL-16 induced Jurkat cell death. It has been reported that the ERK pathway is activated during AICD upon stimulation of the T cell receptor-CD3 complex [37] . However, the IL-16 activates the stress activated protein kinase (SAPK) pathway and p38 MAPK, but, not ERK, in CD4 + macrophages. The IL-16 mediated activation of SAPKs and p38 in macrophages alone does not induce a detectable apoptotic cell death [38] . Our results suggest that, in Jurkat T leukemia cells, the ERK pathway is responsible for the rIL-16-induced cell death. PKC pathway and ERK pathway have a common regulated molecule, nur77 [37] , [39] , which is an orphan nuclear steroid receptor [40] . It transmitted the signal to apoptosis related gene through protein-protein interaction [41] . We have not elucidated every molecule in these signal pathways, but the signal is probably transducted by both PKC and ERK pathway and regulated the effect to proliferation or apoptosis. From our result, the high concentration of IL-16 (10 -5 M) can induce CD4 + T cell apoptosis without any other prestimulation, although no significant difference was observed in the lower concentration IL-16 (10 -9 M) treatment. So a dual role happened to IL-16 in Jurkat cells. The cytokine can stimulate cells proliferation and activation, but also induce apoptosis under certain conditions. It might be a kind of dose effect, but the signal pathway participation makes it looks like a special biological activity. So the function of
IL-16 in CD4
+ T cells needs to be further elucidated.
